BRAF mutation

Multisystem disease remains more challenging, but favourable outcomes can still be achieved with protocol-based treatment. Early recognition, multidisciplinary evaluation, and long-term follow-up are essential due to the risk of relapse and potential late sequelae.

P2, N=48, Not yet recruiting, Fudan University

P=N/A, N=105, Recruiting, AstraZeneca | N=384 --> 105

As CFT1946 progresses through clinical development, the field of oncoprotein-specific degradation will mature. See related article by Kreger et al., p. 438.

P3, N=1069, Recruiting, Gilead Sciences | Trial completion date: Jun 2028 --> Jan 2029

P2/3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

This study provides an overview of the genomic landscape of early-stage nonsquamous NSCLC in Brazilian patients. The high prevalence of mutations observed in our cohort underscores the importance of genomic testing in this setting, enabling selection of patients suitable for targeted approved therapies or clinical trials.

Sonographic features like strap muscle replacement and obtuse tumor-trachea angles are highly specific for ETE and should strongly guide surgical planning. The assessment of RLN invasion, while sensitive, requires caution due to a high false-positive rate. Molecular profiling, particularly for BRAF + TERT co-mutations, significantly enhances risk stratification, underscoring the value of a tailored, multi-parameter preoperative evaluation.

BRAF mutation-unlike KRAS-emerges as a powerful, independent marker of early, multifocal intrahepatic recurrence and inferior post-hepatectomy survival in CRLM. These findings support intensified liver-focused surveillance and early combination adjuvant therapy for patients with BRAF-mutant disease.

The phase III VELOUR trial demonstrated improved outcomes with aflibercept plus FOLFIRI in patients with metastatic colorectal cancer previously treated with oxaliplatin-based regimens...Exploratory integrated analyses suggested OS benefit in RAS/BRAF wild-type iCMS2 tumours (HR 0.56, 95%CI 0.33-0.96) and a significant PFS advantage in bevacizumab-pretreated iCMS3 tumours (HR 0.41, 95%CI 0.20-0.85, q = 0.032)...These findings support integrating genomic and transcriptomic biomarkers to refine patient selection for anti-VEGF therapy, warranting validation in prospective studies. ClinicalTrials.gov number: NCT00561470, registered 15 November 2007.

These data suggest the potential of the 6-gene Duplex Sequencing assay to improve EGFRi patient selection and therapeutic outcomes.

P=N/A, N=400, Completed, Pierre Fabre Medicament | Recruiting --> Completed